Collegium Pharmaceutical (COLL) EBITDA Margin (2016 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly EBITDA Margin of 15.97% for Q1 2026, up 376.0% year-over-year from 3.35% in Q1 2025, and down 46.01% quarter-over-quarter from 29.57% in Q4 2025.
Collegium Pharmaceutical (COLL) EBITDA Margin (2016 - 2026) Analysis & Trends
Collegium Pharmaceutical's EBITDA Margin history runs 11 years deep, the most recent figure standing at 15.97% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 376.0% year-over-year to 15.97%; the TTM figure through Mar 2026 stood at 23.71% (down 364.0% YoY), while the FY2025 annual figure was 23.01%, down 389.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 15.97%, down from 29.57% in the prior quarter.
- The five-year high for EBITDA Margin was 102.34% in Q4 2024, with the low at 11.96% in Q1 2022.
- The 5-year median for EBITDA Margin is 21.87% (2024), against an average of 25.65%.
- The sharpest annual moves came in 2022 and 2025: EBITDA Margin soared 9738 bps in 2022, then slumped 7277 bps in 2025.
- Collegium Pharmaceutical's EBITDA Margin stood at 8.36% in 2022, then soared by 393 bps to 41.2% in 2023, then jumped by 148 bps to 102.34% in 2024, then slumped by 71 bps to 29.57% in 2025, then sank by 46 bps to 15.97% in 2026.
- Business Quant data shows COLL's EBITDA Margin at 15.97% in Q1 2026, 29.57% in Q4 2025, and 29.66% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Collegium Pharmaceutical | 889.49 Mn | 740.17 Mn | 110.29 Mn | 2.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.64% |
| Mar 31, 2026 | 15.97% |
| Dec 31, 2025 | 29.57% |
| Sep 30, 2025 | 29.66% |
| Jun 30, 2025 | 18.67% |
| Mar 31, 2025 | 12.20% |
| Dec 31, 2024 | 102.34% |
| Sep 30, 2024 | 21.87% |
| Jun 30, 2024 | 32.68% |
| Mar 31, 2024 | 34.14% |
| Dec 31, 2023 | 41.20% |
| Sep 30, 2023 | 32.93% |
| Jun 30, 2023 | 26.29% |
| Mar 31, 2023 | 17.01% |
| Dec 31, 2022 | 8.36% |
| Sep 30, 2022 | 16.11% |
| Jun 30, 2022 | 8.99% |
| Mar 31, 2022 | -11.96% |
| Dec 31, 2021 | -89.02% |
| Sep 30, 2021 | 17.95% |